. This observation in healthy subjects has recently been contrasted with the inability to displace [ 11 C]FLB 457 in patients with schizophrenia and alcohol dependence, and is interpreted as a decrease in cortical dopamine transmission in these disorders (Narendran et al., 2014; Slifstein et al., 2015). Nevertheless, concerns remain with respect to the vulnerability of the in vivo binding of [ and increased between-subject variability in amphetamine plasma levels during the post-amphetamine scan (Aalto et al., 2009 
. First, the baseline and post-amphetamine scans were acquired on two different days as opposed to the same day. Second, the post-amphetamine [ 11 C]FLB 457 scan was initiated 5 hours as opposed to 3 hours after oral amphetamine. These changes were made so that individuals could be scanned with the striatal D 2/3 agonist radiotracer [ ]NPA can be used to measure D 2/3 receptors in the striatum but not in the cortex (Narendran et al., 2010) . Such an approach, in which the baseline and post-amphetamine PET scans are acquired on separate days, if successful, would have allowed for the measurement of dopamine release in both the striatum and cortex with a single amphetamine exposure. The need to avoid repeated exposures to amphetamine is desirable for individuals with schizophrenia and addiction, because they are at risk for psychostimulant-induced exacerbation in psychosis and relapse. In this paper, we present the amphetamine-induced displacement of [ when scans (i.e., the baseline and post-amphetamine scans for dopamine release; and the test and retest scans for reproducibility) are acquired on two different days. This reproducibility data from scans acquired on two different days is then contrasted with published data that was acquired on the same day in prior studies (Narendran et al., 2011b) .
| S T U DY D ESI GN A N D ME TH O D S
All data were acquired in imaging protocols approved by the University of Pittsburgh Institutional Review Board. (Frankle et al., 2018) .
The [ 11 C]FLB 457 amphetamine imaging protocol, plasma, and image analyses were conducted according to methods described previously (Narendran et al., 2009 (Narendran et al., , 2014 . Regions of interest included the medial temporal lobe (MTL), dorsolateral prefrontal cortex (DLPFC), orbital frontal cortex (OFC), medial prefrontal cortex (MPFC), anterior cingulate cortex (ACC), temporal cortex (TEMP), parietal cortex (PAR), and occipital cortex (OCC).
The cerebellum (CER) was used as the reference region. PET outcome variables were defined in accordance to the consensus nomenclature for in vivo imaging of reversibly binding radioligands (Innis et al., 2007) . [ 11 C]FLB 457 PET data were also modeled using the simplified reference tissue method (SRTM) because a prior study was able to demonstrate an amphetamine-induced reduction in [ 11 C]FLB 457 BP ND using SRTM but not kinetic modeling (Sandiego et al., 2015) . The primary outcome measure for this study was amphetamine-induced change in BP ND (D BP ND ). This was calculated as the difference between BP ND measured in the post-amphetamine condition (BP ND AMPH ) and BP ND measured in the baseline condition (BP ND BASE ), and expressed as a percentage of BP ND BASE .
| [

C]FLB 457 reproducibility studies
We hypothesized that the inability to displace [ The reproducibility of volume of distribution expressed relative to total plasma ligand concentration (V T ), binding potential expressed relative to total plasma ligand concentration (BP P ), and BP ND were evaluated for their variability and reliability (see Narendran et al., 2011b for detailed methods). The test-retest variability (VAR) was calculated as the absolute value of the difference between the test and retest, divided by the mean of the test and retest values. The reliability of the measurements was assessed by the intraclass correlation coefficient (ICC).
| Statistical analysis
All statistical analyses were performed with IBM SPSS Statistics v.23. Scan parameters (such as injected dose, mass, specific activity, plasma clearance, and V ND ) between scan conditions were contrasted with paired t-tests. Amphetamine effect on the dependent variable, BP ND , was analyzed using a linear mixed model (LMM) with regions of interest as a repeated measure and condition as the fixed factor. Regions and condition by regions interaction were included in the model as explanatory variables. Linear mixed models with the same structure were also used to examine the effect of smoking on DBP ND and modeling method on test-retest variability. Twelve subjects (8 males/4 females; 2 African American/10 Caucasian) participated in the study. The mean age of the subjects was 26 6 4 years.
Six subjects who participated in the study were tobacco users (smokers). 
| Scan parameters
| Region of interest analysis
No significant differences were observed between the [ Table 1 ]. Derivation of BP ND with the SRTM using the cerebellum as an input function provided similar results (see Table 2 ). Pearson product moment correlations between amphetamine plasma levels (t 5 0 minutes and 90 minutes) and DBP ND were not significant (data not shown, all p-values 0.3). . There were no significant differences in f P or C L between the test and the retest conditions.
| Brain analysis
The mean regional V T , BP P , BP ND , and their corresponding VAR and ICC, derived using kinetic analysis are provided in Table 3 . No differences in BP ND were noted between test and retest conditions (paired t test, p > 0.1 in all cortical regions). The VAR and ICC for SRTM derived BP ND is provided in Table 4 . The test-retest variability for regional BP ND derived using SRTM (10% to 18%) was numerically, but not statistically better [LMM, effect of analysis method, F(1, 12) 5 1.1, p 5 0.31; effect of region, F(7, 84) 5 1.6, p 5 0.14; region x condition interaction, F(7, 84) 5 0.58, p 5 0.77] compared to that derived using kinetic analyses (18% to 26%).
| D I SCUSSION
We failed to detect oral amphetamine-induced dopamine release in the cortex with [ (Sandiego et al., 2015) . The inability to displace [ 11 C]FLB 457 BP ND in the cortex following an oral amphetamine challenge was unexpected because three independent groups have replicated this observation in five different cohorts of healthy controls (Table 5 ) (Narendran et al., 2009 (Narendran et al., , 2014 Sandiego et al., 2015 Sandiego et al., , 2018 Slifstein et al., 2015) . (Frankle et al., 2018) . This highlights the continued difficulties in using PET to measure dopamine release in the cortex compared to the striatum. Measuring dopamine release in the striatum is not only robust and easy to replicate, but also minimally influenced by technical factors, such as the D 2/3 radioligand and/or psychostimulant challenge (methylphenidate vs. amphetamine) used in the paradigm, route of administration of the challenge (oral vs. intravenous), and modeling method used to derive BP ND (arterial input vs. reference tissue-based analyses).
The major difference between the current cohort that failed to displace [ Abbreviation: BSSD CV, between subject standard deviation coefficient of variation; WSSD CV, within subject standard deviation coefficient of variation; VAR 6 SD, test/retest variability 6 standard deviation; ICC, intraclass correlation coefficient; CER, regions of interest consisted of the cerebellum; MTL, medial temporal lobe; ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; OFC, orbital frontal cortex; MPFC, medial prefrontal cortex; TC, temporal cortex; PC, parietal cortex; OC, occipital cortex. Note. Values are the mean of seven subjects with each value measured twice. Between-subject and within-subject standard deviations were calculated and expressed as fraction of mean value (coefficient of variation).
acquisition and analyses methods were used (see Table 6 ). Such differences between the same day and different day test-retest variability have not been evidenced with [
11 C]raclopride, the reference radiotracer used to measure D 2/3 receptors in the striatum. [ 11 C]raclopride PET studies conducted by the imaging group at Turku in Finland have reported the same Day (2.5 hours apart) and different day (five weeks apart) test-retest variability to be within 5% to 6% and 4% to 9% for BP ND in the striatal subdivisions (Alakurtti et al., 2011 (Alakurtti et al., , 2015 . Next, we wanted to understand whether technical challenges involved with characterizing the metabolite-corrected arterial input function for [ The test-retest variability for BP ND in the eight cortical regions derived using SRTM (10% to 18%) was numerically, but not statistically improved compared to the kinetic analyses (18% to 26%). The minimal improvement in reproducibility noted with SRTM suggests a possible role for other factors contributing to poor reproducibility in the different day scan protocol. Unfortunately, these other factors, which may include, but are not limited to the anticipation/stress/pain levels associated with arterial line insertions, sleep quality/quantity, last use of caffeine/nicotine/alcohol use and stage of the menstrual cycle, etc., tend to be difficult to control across different days in human studies. The poor reproducibility in the different day scan paradigm may also be a physiological consequence of the relatively low baseline dopamine concentrations in the cortex, which is less stable when measured across days. Consistent with this notion, D 2/3 PET studies that have attempted to measure baseline dopamine concentrations in the cortex with the dopamine depleting agent alpha-methyl-para-tyrosine (AMPT) have been unsuccessful due to the need to measure a relatively small effect (DBP ND ) with increased variability (Cropley et al., 2008; Frankle et al., 2010) .
The poor reproducibility for baseline [ 11 C]FLB 457 BP ND in the different day scan paradigm reported here is also inconsistent with the low testretest variability reported for the post-amphetamine BP ND when measured on different days (Narendran, Himes, & Mason, 2013) . The exact reasons that lead to poor reproducibility in the baseline (18% to 26% in cortical ROIs in Table 3 weeks of guanfacine treatment reported that guanfacine led to a decrease in dopamine release (DBP ND ) (Sandiego et al., 2018) . However, the Abbreviation: BSSD CV, between subject standard deviation coefficient of variation; WSSD CV, within subject standard deviation coefficient of variation; VAR 6 SD, test/retest variability 6 standard deviation; ICC, intraclass correlation coefficient; CER, regions of interest consisted of the cerebellum; MTL, medial temporal lobe; ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; OFC, orbital frontal cortex; MPFC, medial prefrontal cortex; TC, temporal cortex; PC, parietal cortex; OC, occipital cortex. ) in the current study versus 2.5 to 3 hours in all previously published studies. NA: Data is not available for these regions. a DBP ND is from data modeled using a simplified reference tissue model as opposed to a two-tissue compartment model. b Data shown for OFC is from a re-analysis of the original study data that was published in (Narendran et al., 2011b) .
smaller DBP ND measured in the guanfacine-treated relative to the untreated condition was attributable to a nonsignificant 4-12% decrease in baseline (not post-amphetamine) BP ND after chronic guanfacine treatment. The reproducibility for BP ND, which is poor in the baseline and good in postamphetamine conditions may have introduced a bias on DBP ND measured after guanfacine treatment. To exclude such bias, future longitudinal This is based on the fact that the reproducibility for [ 11 C]FLB 457 BP ND is significantly better when scans are performed on same compared to different days (Narendran et al., 2011b and data from this study).
2
Restrict injected mass for [ 11 C]FLB 457 0.6 micrograms to ensure studies are conducted at tracer dose (i.e., 5% occupancy). This is necessary to avoid carrier-mass induced changes in BP ND when the baseline and postamphetamine scans are performed on same day (Sudo et al., 2001 (Narendran et al., 2011a) . Thus, it is necessary to exclude amphetamine-induced changes in cerebellum V ND, which in turn will impact the primary outcome measures, i.e., DBP ND. For example, in a clinical PET study, an amphetamine-induced decrease in V ND in patients, but not in controls could bias the between-group comparison of DBP ND. However, once no group differences in DV ND is established with kinetic analyses, it might be reasonable to use SRTM to derive BP ND and DBP ND . The rationale for this is based on a prior study that showed oral amphetamine-induced displacement of BP ND , when BP ND was derived with SRTM, but not kinetic analyses (Sandiego et al., 2015) . This is likely due to the lower within-subject variability when DBP ND is arrived with the SRTM compared to kinetic analyses. Finally, more advanced modeling methods (such as a modified two-tissue compartment kinetic analyses in which V ND and the specific binding dissociation constant, k4 are fixed to a single value across cortical regions for both baseline and post-amphetamine scans) that account for the D 2/3 specific binding have been recently used to measure an amphetamine-induced DBP ND (Slifstein et al., 2015) . Such advanced modeling methods may be robust in detecting relatively small amphetamine-induced changes in BP ND when the baseline BP ND values are relatively small as with [ 11 C]FLB 457 in the cortex.
4
Use oral d-amphetamine at 0.5 mg kg 21 as a challenge to stimulate cortical dopamine release (as opposed to the intravenous formulation, or oral methylphenidate).
Oral compared to intravenous amphetamine is associated with less plasma variability during the post-amphetamine scan (Aalto et al., 2009; Narendran et al., 2009 ). This may be critical to measuring dopamine release in the cortex compared to the striatum (see discussion section). Also, methylphenidate which releases dopamine primarily by inhibiting the dopamine and norepinephrine transporters (as opposed to amphetamine which releases dopamine by additional mechanisms such as vesicular release, reverses dopamine transporter, etc.,), and lower doses (less than 0.5 mg kg
21
) of amphetamine may not displace [ 11 C]FLB 457 BP ND (Montgomery et al., 2007) .
5
The post-amphetamine scan should be initiated at 3 hours following the oral amphetamine challenge.
To ensure that the post-amphetamine [ 11 C]FLB 457 scan corresponds to the peak plasma amphetamine levels (and presumably peak dopamine release in cortex) (Angrist, Corwin, Bartlik, & Cooper, 1987) . This is important because it is not known whether amphetamine -induced DBP ND is prolonged beyond peak dopamine release in the cortex as demonstrated in the striatum.
6
The [
11 C]FLB 457 amphetamine imaging paradigm is more robust when used in younger individuals.
BP ND values in prefrontal cortical regions fall below 0.5 in individuals with > 35 years old (Kaasinen et al., 2000 (Kaasinen et al., , 2002 Narendran et al., 2009) . Displacing a relatively low BP ND with amphetamine leads to increased variability DBP ND . ]FLB 457 data in n 5 6 subjects from (Narendran et al., 2011b) . Different day test-retest variability data are from n 5 7 subjects in this study (see Table 3 ).
GERTLER ET AL.
| 7 of 9 studies that use [ 11 C]FLB 457 and amphetamine should consider the inclusion of a placebo-control group to examine the impact of reproducibility on baseline, post-amphetamine, and percent change in BP ND .
The mean amphetamine plasma level at the time of initiation and completion of the post-amphetamine [ 11 C]FLB 457 PET scan in this study was 68 6 9 and 58 6 10 ng mL 21 (t 5 0 and 90 minutes relative to post-amphetamine scan). These values are 20% lower than the mean amphetamine plasma values (80 6 10 and 70 6 10) reported in our largest healthy control cohort that was successful in displacing [ 11 C]FLB 457 BP ND (Narendran et al., 2014) . This difference between means was anticipated because the post-amphetamine scan was initiated at five hours, as opposed to three hours, following the oral amphetamine challenge in this study. This adjustment from three to five hours between baseline and postamphetamine scan was done to accommodate the [ 11 C]NPA scan, which was necessary to measure striatal dopamine release. Studies with D 2/3 radiotracers in the striatum (and globus pallidus) have shown that it takes 24-48 hours for BP ND to return back to baseline following an amphetamine challenge (Cardenas, Houle, Kapur, & Busto, 2004; Carson, Vuong, Watabe, Herscovitch, & Eckelman, 2001; Laruelle et al., 1997; Narendran et al., 2007) . These investigations have also shown that the DBP ND measured following an acute amphetamine challenge in the striatum is essentially unchanged for the first six hours. It is not known whether the same holds true for [ 11 C]FLB 457 in a region such as the prefrontal cortex, where the clearance of dopamine from the synapse does not occur via dopamine transporters. In the absence of these data, one cannot exclude the possibility that lower amphetamine plasma levels during the [ 11 C]FLB 457 scan led to the inability to detect dopamine release in this study. We found no relationship between amphetamine plasma levels and DBP ND to support this notion. This is likely because of the low variability in amphetamine plasma levels seen in this study. Lastly, we cannot exclude the contribution from unique dopamine clearance mechanisms in the cortex (compared to primarily dopamine transporter-mediated uptake in striatum) that include diffusion into the extracellular space, monoamine oxidase -A (MAO-A), catechol-O-methyl-transferase (COMT), norepinephrine transporter (NET), etc., leading to a greater degradation of synaptic dopamine at 5 versus 3 hours, and influencing the ability to detect a change in BP ND (Kaenmaki et al., 2010; Tammimaki, Aonurm-Helm, Kaenmaki, & Mannisto, 2016) .
In summary, we failed to displace [ 11 C]FLB 457 following an oral amphetamine challenge in a cohort of healthy individuals who underwent the baseline and post-amphetamine scans on different days. These results, which are inconsistent with our prior reports, highlight the methodological challenges that continue to plague the field with respect to imaging dopamine release in the cortex with PET. In closing, in Table 7 we list a few suggestions to maximize success for future investigations planning to use [ 
